$795.71
+12.87 (+1.64%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ESLT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 14 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, +9 more) · FINRA short interest 3.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Proof of Concept - Digital Electro-optical Surgical Platform as Replacement for Operational MicroscopesNCT02715388Field of view of GlasScope surgical microscopeOpen-label · Treatment | Not applicable | Completed | Device: GlasScope Surgical Microscope | Retinal Detachment | 72 | Jan 2022actual | 2022-04-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19